NCT01916850

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

A Phase 1b, Single-center, Double-blind, Randomized, Placebo-controlled Study on the Safety, Tolerability, and Pharmacokinetic Effects of Multiple Doses of LX4211 400 mg qd and LX4211 800 mg qd in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of multiple oral doses of LX4211 400 mg and LX4211 800 mg (administered once daily for 10 consecutive days) in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LX4211 400 mg
DRUG	LX4211 800 mg
DRUG	LX4211 Placebo

Timeline

• Start date: 2013-08-01
• Primary completion: 2013-10-01
• First posted: 2013-08-06
• Last updated: 2013-10-30

Locations

1 site across 1 country: United States